May 2007
Volume 48, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2007
Clinical Observation of Photodynamic Therapy With Visudyne for Polypoidal Choroidal Vasculopathy
Author Affiliations & Notes
  • C.-J. Jin
    Dept of Ophthalmology, Zhongshan Ophthalmic Center, Guangzhou, China
  • Y. Zhang
    Dept of Ophthalmology, Zhongshan Ophthalmic Center, Guangzhou, China
  • Z. Tian
    Dept of Ophthalmology, Zhongshan Ophthalmic Center, Guangzhou, China
  • N. Kong
    Dept of Ophthalmology, Zhongshan Ophthalmic Center, Guangzhou, China
  • Footnotes
    Commercial Relationships C. Jin, None; Y. Zhang, None; Z. Tian, None; N. Kong, None.
  • Footnotes
    Support Grant of Ministry of Public Health of China
Investigative Ophthalmology & Visual Science May 2007, Vol.48, 4567. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      C.-J. Jin, Y. Zhang, Z. Tian, N. Kong; Clinical Observation of Photodynamic Therapy With Visudyne for Polypoidal Choroidal Vasculopathy. Invest. Ophthalmol. Vis. Sci. 2007;48(13):4567.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose:: To study the clinical effect of photodynamic therapy (PDT) with Visudyne for polypoidal choroidal vasculopathy (PCV).

Methods:: Ten patients (10 eyes) with PCV who were diagnosed by fundus fluorescein angiography (FFA),indocyanine green angiography (ICGA),optic coherence tomography (OCT) were treated by PDT with Visudyne. Eight cases (8 eyes) were male, the other two cases (2 eyes) were female. Their ages ranged from 50 to 77 years, mean(59.5±9.70)years. The best corrected visual activity (BCVA) before PDT was (0.22±0.14).The changes of BCVA,fundus photography, FFA and ICGA before and after PDT were compared. Follow-up time varied from 6 months to 36 months, mean(24±9.70)months.

Results:: One month after PDT the BCVA was(0.26±0.15),FFA and/or ICGA showed no leakage in 4 eyes, leakage reduced in 3 eyes, slight leakage in 2 eyes.At the last follow-up, the BCVA was(0.29±0.11), FFA / ICGA showed no leakage in 7 eyes, slight leakage in 2 eyes. No systemic or local adverse effect was found during or after PDT, except 1 eye with extensive subretinal hemorrhage suffered vitreous hemorrhage one month after PDT.

Conclusions:: Photodynamic therapy with Visudyne may stop or reduce the macular leakage, facilitate the absorption of hemorrhage, exudates and edema, stabilize or increase the patients’ visual activities. It could be a choice for the treatment of PCV.

Keywords: age-related macular degeneration • photodynamic therapy • choroid: neovascularization 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×